Open Access

Gemfibrozil reduces lipid accumulation in SMMC‑7721 cells via the involvement of PPARα and SREBP1

  • Authors:
    • Xiaonan Zhang
    • Song Wang
    • Linlin Hu
    • Jian Wang
    • Yajing Liu
    • Ping Shi
  • View Affiliations

  • Published online on: December 5, 2018     https://doi.org/10.3892/etm.2018.7046
  • Pages: 1282-1289
  • Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Gemfibrozil (GEM) is a member of the fibrate class of lipid‑lowering pharmaceuticals and has been widely used in the therapy of different forms of hyperlipidemia and hypercholesterolemia. Non‑alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease and is becoming an important public health concern worldwide. However, there is little knowledge about the effects of GEM on NAFLD. In the present study, oleate‑treated human hepatoma SMMC‑7721 cells were utilized to investigate the role of GEM in regulating hepatic lipid metabolism. The present results demonstrated that GEM attenuated excessive intracellular triglyceride content in the steatosis model. Upregulation of peroxisome proliferator‑activated receptor α (PPARα) protein and sterol regulatory element‑binding protein 1 (SREBP1) was detected following treatment with GEM. Additionally, reverse transcription‑polymerase chain reaction analysis demonstrated that GEM increased the downstream genes related to PPARα and SREBP1, including carnitine palmitoyltransferase 2, acyl‑coA oxidase 1, hydroxyacyl‑CoA dehydrogenase, LIPIN1 and diacylglycerol O‑acyltransferase 1. These findings demonstrated that GEM alleviated hepatic steatosis via the involvement of the PPARα and SREBP1 signaling pathways, which enhances lipid oxidation and interferes with lipid synthesis and secretion. Taken together, the data provide direct evidence that GEM may lower lipid accumulation in hepatocellular steatosis cells in vitro and that it may have a potential therapeutic use for NAFLD.
View Figures
View References

Related Articles

Journal Cover

February-2019
Volume 17 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhang X, Wang S, Hu L, Wang J, Liu Y and Shi P: Gemfibrozil reduces lipid accumulation in SMMC‑7721 cells via the involvement of PPARα and SREBP1. Exp Ther Med 17: 1282-1289, 2019
APA
Zhang, X., Wang, S., Hu, L., Wang, J., Liu, Y., & Shi, P. (2019). Gemfibrozil reduces lipid accumulation in SMMC‑7721 cells via the involvement of PPARα and SREBP1. Experimental and Therapeutic Medicine, 17, 1282-1289. https://doi.org/10.3892/etm.2018.7046
MLA
Zhang, X., Wang, S., Hu, L., Wang, J., Liu, Y., Shi, P."Gemfibrozil reduces lipid accumulation in SMMC‑7721 cells via the involvement of PPARα and SREBP1". Experimental and Therapeutic Medicine 17.2 (2019): 1282-1289.
Chicago
Zhang, X., Wang, S., Hu, L., Wang, J., Liu, Y., Shi, P."Gemfibrozil reduces lipid accumulation in SMMC‑7721 cells via the involvement of PPARα and SREBP1". Experimental and Therapeutic Medicine 17, no. 2 (2019): 1282-1289. https://doi.org/10.3892/etm.2018.7046